banner infections beyond covid-19

Recent Publications on Infectious Diseases

Published on 18/05/2022

JPT offers a broad range of innovative peptide products that cover antigens of many known viruses and bacteria. With continuously emerging pathogens and their respective variants posing a threat to human and environmental health, we remain vigilant in providing the respective tools for vaccine development and antigen-specific immunotherapy, which can be applied in a multitude of studies: 

  • T-cell and B-cell epitope discovery
  • Clinical trial immune monitoring
  • Blood- and sero test development
  • Cross-reactivity testing
  • Cell therapy development of new potential vaccine delivery formats

Here we demonstrate the range of our catalog and customizable products on the basis of recent publications:

  1. Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
    Woldemeskel et al., Clinical Infectious Diseases (2022)
    Keywords: SARS-CoV-2, mRNA Vaccine, clinical trial, Immune monitoring, omicron
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) & (Spike Omicron)
  2. Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients
    Peter et al., Molecular Therapy Methods (2022)
    Keywords: SARS-CoV-2, Vaccine, Solid Organ Transplant, Tacrolimus, Immune Response
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), (VME1), (NCAP) (VEMP), (APA3), (NS7A), (NS7B), (ORF9B), (ORF10), (Spike Alpha), (Spike Beta), (Spike Delta), (Spike Omicron)
  3. SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants
    Panikkar et al., PLoS Pathogens (2022)
    Keywords: SARS-CoV-2 variants, adoptive immunotherapy, Immune Monitoring,
    Products used: PepMix SARS-CoV-2 (NCAP), (APA3), (VME1), (Spike Glycoprotein)
  4. SARS-CoV-2 mRNA vaccination fails to elicit humoral and cellular immune responses in multiple sclerosis patients receiving fingolimod
    Meyer-Arndt et al., MedRxiv (2022)
    Keywords: SARS-CoV-2 Vaccine, Humoral Immune Response, Multiple Sclerosis, Fingolimod
    Product used: PepStar SARS-CoV-2 Spike Glycoprotein Variant Collection (incl. Omicron)
  5. Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV
    Wang et al., Vaccines (2022)
    Keywords: HIV, AIDS, vaccine PDPHV, broadly binding & functional antibodies, B cells
    Product used: PepStar HIV-1 env (gp120 protein + signal peptide)
  6. Differential localization and limited cytotoxic potential of duodenal CD8+ T cells
    Mvaya et al., JCI Insight (2022)
    Keywords: HIV, duodenal tissue, CD8+ cells, increase cytotoxic potential of immunetherapy
    Products used: PepMix HIV-1 (NEF) Ultra(POL) Ultra(GAG) Ultra 
  7. Direct Evidence for Viral Antigen Presentation during Latent Cytomegalovirus Infection
    Lemmermann & Reddehase, Pathogens (2021)
    Keywords: CMV, memory inflation, CD8+ T-cell response, viral latency
    Product used: Custom Peptide Services

Check our website for more publications .
If we do not have your antigen of interest in stock, please check out our custom options or reach out to our customer support.

Check our list of products, click and go.

Get a quote